

VGI Health Technology Limited – NAFLD/NASH Phase II Clinical Study commences dosing patients

Sydney, New South Wales, 5 October 2022 – VGI Health Technology Limited (**NSX:VTL**) is pleased to announce that its wholly owned subsidiary, Invictus Ops Pty Ltd (**Invictus**), has commenced dosing of patients for its Phase II clinical study in Non-Alcoholic Fatty Liver Disease (**NAFLD**)/Non-Alcoholic SteatoHepatitis (**NASH**).

Dosing of **Invictus'** **NAFLD/NASH** drug candidate IVB001 has commenced for 1 patient at The Gallipoli Medical Research Foundation in Queensland and 3 patients at The John Hunter Hospital in New South Wales. A total of 80 patients will be recruited and dosed for this study which is a randomised, double-blind, placebo-controlled Phase II clinical study on **NAFLD/NASH** to analyse the efficacy and safety of IVB001, a drug candidate based on the non-invasive and direct delivery of tocotrienols using **Invictus'** patented transmucosal delivery platform.

Dr David Kingston, the Chief Scientific Officer of VTL, said "Unlike many other Phase II clinical studies, the present study is based on efficacy signals derived from clinical studies on orally administered tocotrienols rather than animal studies and we have seen some promising results in **NAFLD/NASH** patients who have been administered a dietary supplement which is closely aligned to the drug candidate IVB001. This study is showing a lot of promise and we hope to be able to address the great unmet need presented by **NAFLD/NASH**."

For more information please contact:

Dr Glenn Tong, CEO and Managing Director
Ph: +61 (0) 412 193 350

Mrs Catriona Glover, Company Secretary
Tel: +61 (0) 402 328 200

About VGI Health Technology Limited

VGI Health Technology Limited trading as VGI Health Technology is an Australian public listed company (NSX:VTL). VTL refers to recent announcements about the divestment of its wholly owned subsidiary Invictus BioPharma Pty Ltd. Post completion of this transaction, VTL will be focussed on manufacturing, marketing and selling novel dietary supplements based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery and exercise endurance. The Company has a product development program for evidence-based nutraceuticals.

For more information see: <https://www.vgiht.com>

Investors interested in trading shares on the NSX should contact a broker who is an NSX Participant:
https://www.nsx.com.au/broker_list_print.asp